Refine
Year of publication
Language
- English (204)
Has Fulltext
- yes (204)
Is part of the Bibliography
- no (204)
Keywords
- BESIII (14)
- Branching fraction (9)
- e +-e − Experiments (9)
- Hadronic decays (5)
- Particle and Resonance Production (5)
- Branching fractions (4)
- Lepton colliders (4)
- Quarkonium (4)
- Charm Physics (3)
- Charmed mesons (3)
- Charmonium (3)
- Electroweak interaction (3)
- Exotics (3)
- Initial state radiation (3)
- Spectroscopy (3)
- e+-e− Experiments (3)
- Bhabha (2)
- Charm physics (2)
- Cross section (2)
- Electroweak Interaction (2)
- Hadronic cross section (2)
- Leptonic, semileptonic & radiative decays (2)
- Muon anomaly (2)
- Particle decays (2)
- Pion form factor (2)
- QCD (2)
- Angular distribution (1)
- Annihilation (1)
- BESIII detector (1)
- Born cross section measurement (1)
- CP violation (1)
- Charmonium (-like) (1)
- Covariance matrix (1)
- Cross section measurements (1)
- D meson (1)
- D0 and D+ mesons (1)
- Dalitz decay (1)
- Dark photon (1)
- Dark sector (1)
- D⁰ meson (1)
- Electromagnetic form factor (1)
- Electromagnetic form factors (1)
- Experimental nuclear physics (1)
- Experimental particle physics (1)
- FOS: Physical sciences (1)
- Flavor changing neutral currents (1)
- Flavor symmetries (1)
- Flavour Physics (1)
- Form factors (1)
- HIV-1 (1)
- Hadrons (1)
- High Energy Physics - Experiment (hep-ex) (1)
- Hyperons (1)
- Invisible decays (1)
- Lactobacillus (1)
- Neutrinos (1)
- Particle and resonance production (1)
- Particle phenomena (1)
- Polarization (1)
- Proton (1)
- Quantum chromodynamics (1)
- R value (1)
- Radiative decay (1)
- Rare decays (1)
- Semi-leptonic decays (1)
- Techniques Electromagnetic calorimeters (1)
- Triple quarkonia (1)
- VHH (1)
- XL probe (1)
- Y (4260) (1)
- Y states (1)
- center-of-mass energy (1)
- charmonium-like states (1)
- dimuon (1)
- diphoton (1)
- e+e − annihilation (1)
- e+e⁻ − Experiments (1)
- e+e− Experiments (1)
- e+e− annihilation (1)
- electron-positron collision (1)
- hadron spectroscopy (1)
- hadronic events (1)
- helicity amplitude analysis (1)
- humanized mouse model (1)
- inclusive J/ψ decays (1)
- liver fibrosis (1)
- luminosity (1)
- nanobodies (1)
- neutralization (1)
- number of J/ψ events (1)
- obese (1)
- passive immunization (1)
- prophylactic vaccine (1)
- tetraquark (1)
- transient elastography (1)
- trigger efficiency (1)
- vector (1)
- Λ+c baryon (1)
- Σ hyperon (1)
Institute
- Physik (202)
- Medizin (2)
- Georg-Speyer-Haus (1)
Observation of η′ → π⁺π⁻μ⁺μ⁻
(2021)
Using (1310.6±7.0)×106 𝐽/𝜓 events acquired with the BESIII detector at the BEPCII storage rings, the decay 𝜂′→𝜋+𝜋−𝜇+𝜇− is observed for the first time with a significance of 8𝜎 via the process 𝐽/𝜓→𝛾𝜂′. We measure the branching fraction of 𝜂′→𝜋+𝜋−𝜇+𝜇− to be ℬ(𝜂′→𝜋+𝜋−𝜇+𝜇−)=(1.97±0.33(stat)±0.19(syst))×10−5, where the first and second uncertainties are statistical and systematic, respectively
The rare decay 𝜂′→𝜋+𝜋−𝑒+𝑒− is studied using a sample of 1.3×109 𝐽/𝜓 events collected with the BESIII detector at BEPCII in 2009 and 2012. The branching fraction is measured with improved precision to be (2.42±0.05stat±0.08syst)×10−3. Due to the inclusion of new data, this result supersedes the last BESIII result on this branching fraction. In addition, the 𝐶𝑃-violating asymmetry in the angle between the decay planes of the 𝜋+𝜋−-pair and the 𝑒+𝑒−-pair is investigated. A measurable value would indicate physics beyond the standard model; the result is 𝒜𝐶𝑃=(2.9±3.7stat±1.1syst)%, which is consistent with the standard model expectation of no 𝐶𝑃-violation. The precision is comparable to the asymmetry measurement in the 𝐾0𝐿→𝜋+𝜋−𝑒+𝑒− decay where the observed (14±2)% effect is driven by a standard model mechanism.
Background: Transient elastography (TE) has been validated as an effective noninvasive tool for the assessment of liver fibrosis. The XL probe is a new probe that was initially designed for use in patients with obesity. A meta-analysis was performed to assess the feasibility and efficacy of TE using the XL probe.
Methods: In September 2016, we systematically searched the PubMed and Science Direct search engines. The feasibility of TE was evaluated based on the failure rate and the results of the unreliable liver stiffness measurement (LSM). The efficacy of TE was measured using sensitivity, specificity, and summary receiver-operating characteristic as measures/indices assessed in different stages of fibrosis. Heterogeneity was measured using the chi-squared test and the Q-statistic. We used the 95% confidence interval (95% CI) as an effect measure.
Results: We included 8 studies in the meta-analysis. When the XL was compared to the M probe, the former showed a lower risk of failure rate [relative risk (RR) 0.24, 95% CI 0.14–0.38]. In patients with a body mass index ≥30 kg/m2, the XL probe showed a statistically significantly lower risk of failure rate (RR 0.16, 95% CI 0.08–0.32) but no significant improvement (RR 0.76, 95% CI 0.50–1.16) in the unreliable LSM result. In patients showing liver fibrosis stage ≥F2, the XL probe showed a sensitivity of 0.56 (95% CI 0.39–0.72), specificity of 0.71 (95% CI 0.61–0.79), and an area under the curve (AUC) of 0.71. The results observed in patients with liver fibrosis stage F4 were more promising with a sensitivity of 0.84 (95% CI 0.76–0.90), specificity of 0.78 (95% CI 0.70–0.84), and an AUC of 0.88.
Conclusion: TE using the XL probe demonstrates significant diagnostic utility in patients with liver fibrosis and is likely to be more reliable than the M probe in patients with obesity. Large prospective multicenter studies are, however, necessary to establish the new cut-off values to be used for the XL probe in patients with obesity.
In the absence of an active prophylactic vaccine against HIV-1, passively administered, broadly neutralizing antibodies (bnAbs) identified in some chronically infected persons were shown to prevent HIV-1 infection in animal models. However, passive administration of bnAbs may not be suited to prevent sexual HIV-1 transmission in high-risk cohorts, as a continuous high level of active bnAbs may be difficult to achieve at the primary site of sexual transmission, the human vagina with its acidic pH. Therefore, we used Lactobacillus, a natural commensal in the healthy vaginal microbiome, to express bn nanobodies (VHH) against HIV-1 that we reported previously. After demonstrating that recombinant VHHA6 expressed in E. coli was able to protect humanized mice from mucosal infection by HIV-1Bal, we expressed VHHA6 in a soluble or in a cell-wall-anchored form in Lactobacillus rhamnosus DSM14870. This strain is already clinically applied for treatment of bacterial vaginosis. Both forms of VHHA6 neutralized a set of primary epidemiologically relevant HIV-1 strains in vitro. Furthermore, VHHA6 was still active at an acidic pH. Thus, lactobacilli expressing bn VHH potentially represent an attractive vector for the passive immunization of women in cohorts at high risk of HIV-1 transmission.